JP2007500134A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500134A5
JP2007500134A5 JP2006521307A JP2006521307A JP2007500134A5 JP 2007500134 A5 JP2007500134 A5 JP 2007500134A5 JP 2006521307 A JP2006521307 A JP 2006521307A JP 2006521307 A JP2006521307 A JP 2006521307A JP 2007500134 A5 JP2007500134 A5 JP 2007500134A5
Authority
JP
Japan
Prior art keywords
dosage form
buprenorphine
withdrawal syndrome
kit
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/024010 external-priority patent/WO2005011579A2/en
Publication of JP2007500134A publication Critical patent/JP2007500134A/ja
Publication of JP2007500134A5 publication Critical patent/JP2007500134A5/ja
Pending legal-status Critical Current

Links

JP2006521307A 2003-07-25 2004-07-26 依存性退薬症状の治療 Pending JP2007500134A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49040703P 2003-07-25 2003-07-25
PCT/US2004/024010 WO2005011579A2 (en) 2003-07-25 2004-07-26 Treatment of dependence withdrawal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011179129A Division JP2011252020A (ja) 2003-07-25 2011-08-18 依存性退薬症状の治療

Publications (2)

Publication Number Publication Date
JP2007500134A JP2007500134A (ja) 2007-01-11
JP2007500134A5 true JP2007500134A5 (https=) 2007-04-19

Family

ID=34115390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006521307A Pending JP2007500134A (ja) 2003-07-25 2004-07-26 依存性退薬症状の治療
JP2011179129A Pending JP2011252020A (ja) 2003-07-25 2011-08-18 依存性退薬症状の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011179129A Pending JP2011252020A (ja) 2003-07-25 2011-08-18 依存性退薬症状の治療

Country Status (28)

Country Link
US (1) US8637073B2 (https=)
EP (1) EP1646328B1 (https=)
JP (2) JP2007500134A (https=)
KR (1) KR100829492B1 (https=)
CN (1) CN1829482B (https=)
AT (1) ATE375149T1 (https=)
AU (1) AU2004261182B2 (https=)
BR (1) BRPI0412931A (https=)
CA (1) CA2530005C (https=)
CY (1) CY1107262T1 (https=)
DE (1) DE602004009449T2 (https=)
DK (1) DK1646328T3 (https=)
EA (1) EA009921B1 (https=)
ES (1) ES2295929T3 (https=)
GE (1) GEP20125454B (https=)
HR (1) HRP20070476T3 (https=)
IL (1) IL173346A (https=)
IS (1) IS2630B (https=)
MA (1) MA28004A1 (https=)
MX (1) MXPA06000991A (https=)
NO (1) NO333189B1 (https=)
NZ (1) NZ545505A (https=)
PL (1) PL1646328T3 (https=)
PT (1) PT1646328E (https=)
SI (1) SI1646328T1 (https=)
UA (1) UA81056C2 (https=)
WO (1) WO2005011579A2 (https=)
ZA (1) ZA200510069B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
CN101316623A (zh) * 2005-09-30 2008-12-03 Tti优而美株式会社 系统输送活性剂的离子电渗方法和装置
WO2009106831A2 (en) * 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
US8163731B2 (en) * 2008-08-20 2012-04-24 Rhodes Technologies Method and dosage regimens for eliminating a chemical substance in blood
US9879204B2 (en) 2010-03-17 2018-01-30 Method Products, Pbc Liquid cleaning compositions with lower freezing point
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
TW201307553A (zh) 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸(dha)及其他長鏈多元不飽和脂肪酸(lc-pufa)之技術
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
DK3400066T3 (da) * 2016-01-08 2021-10-18 Ohio State Innovation Foundation Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN107648234A (zh) * 2017-08-04 2018-02-02 中国人民解放军第二军医大学 一种治疗吗啡成瘾戒断症状的阿片类药物组合物
IL277801B2 (en) * 2018-04-09 2025-06-01 Katana Pharmaceuticals Inc Oxytocin compositions and methods of use
WO2021043771A1 (en) * 2019-09-02 2021-03-11 Camurus Ab Formulations and treatment methods
CA3207013A1 (en) 2021-02-01 2022-08-04 Xinhua Li Sequestration compounds for treatment of substance use disorder and uses thereof
WO2024036337A2 (en) * 2022-08-12 2024-02-15 Bio Ventures, Llc Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
DE3939376C1 (https=) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
JPH06183956A (ja) 1992-12-24 1994-07-05 Teisan Seiyaku Kk 安定な貼付用の製剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug

Similar Documents

Publication Publication Date Title
JP2011252020A5 (https=)
JP2007500134A5 (https=)
JP2009544619A5 (https=)
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
JP2011511071A5 (https=)
JP2005528359A5 (https=)
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
JP2002523370A5 (https=)
JP2006513184A5 (https=)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
Dowling et al. Relative bioavailability of ketoprofen 20% in a poloxamer-lecithin organogel
US10624945B2 (en) Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
RU2006137349A (ru) Композиции продолжительного действия на основе налтрексона
KR20060039867A (ko) Hiv 치료를 위한 조성물 및 방법
JP2009539916A5 (https=)
CA2563058A1 (en) Supportive treatment of liver disease
CN1548036A (zh) 含有阿卡宁类化合物作为活性成分的药物
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP2005513105A5 (https=)
JP2005508323A5 (https=)
JP2022512158A5 (https=)
CN1298389C (zh) 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
CN1063632C (zh) 一种治疗皮肤病的外用搽剂
CN103263435B (zh) 聚维酮碘的制药用途